What's happening
This bill requires that patients and providers receive detailed written notice, including appeal instructions, when step therapy override requests are denied by insurers.
Why it matters
Enhances transparency. By requiring insurers to specify the clinical reasons and rationale behind step therapy override denials, patients and providers are better equipped to understand the decision and address specific issues in any appeal.
Empowers timely appeals. Mandating clear, written instructions for both standard and expedited appeals (including how to request external reviews) means patients and providers can more readily challenge adverse determinations, reducing delays in accessing necessary treatments.
Improves patient-provider communication. Both the patient (or their representative) and the prescribing health care professional must receive the notice, ensuring all parties are aware of the decision and next steps, which helps coordinate care and advocacy.
Requires disclosure of alternatives and criteria. Insurers must list any alternative covered medications and the clinical review criteria used, as well as any additional information needed for appeals, making the process more navigable and potentially reducing administrative burdens and frustration.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Require Denial Notice Details
Plain English, a few words. Used as the page title.
Sponsors
Assembly Member · Assembly District 108
1 Co-sponsor
History
- Referred to insurance
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Require Step Therapy Denial Notices
In Senate Committee · Insurance · Sponsor Neil D. Breslin
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
9265
IN ASSEMBLY
February 9, 2022
Introduced by M. of A. McDONALD -- read once and referred to the Committee on Insurance
AN ACT to amend the insurance law and the public health law, in relation to requiring notice of adverse step therapy determinations
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subsection (a) of section 4902 of the insurance law is amended by adding a new paragraph 14 to read as follows:
(14) Establishment of a written procedure to assure that the notice of an adverse determination in relation to a step therapy protocol override determination request includes:
(i) the reasons for the determination including the clinical rationale, if any;
(ii) instructions on how to initiate standard and expedited appeals pursuant to section four thousand nine hundred four of this article and an external appeal pursuant to section four thousand nine hundred fourteen of this article;
(iii) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal.
§ 2. Section 4903 of the insurance law is amended by adding a new subsection (e-1) to read as follows:
(e-1) Notice of an adverse determination made by a utilization review agent in relation to a step therapy protocol override determination request shall be made in writing to the insured or the insured's authorized representative and the insured's prescribing health care professional as defined in subsection (f) of section forty-nine hundred of this chapter, and shall include:
(i) the reasons for the determination including the clinical rationale, if any;
(ii) instructions on how to initiate standard and expedited appeals pursuant to section four thousand nine hundred four of this article and
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD14434-01-2
an external appeal pursuant to section four thousand nine hundred fourteen of this article;
(iii) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal.
§ 3. Subdivision 1 of section 4902 of the public health law is amended by adding a new paragraph (l) to read as follows:
(l) Establishment of a written procedure to assure that the notice of an adverse determination in relation to a step therapy protocol override determination request includes: (i) the reasons for the determination including the clinical rationale, if any; (ii) instructions on how to initiate standard and expedited appeals pursuant to subdivision two of section forty-nine hundred four of this title and an external appeal pursuant to section forty-nine hundred fourteen of this article; (iii) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal.
§ 4. Section 4903 of the public health law is amended by adding a new subdivision 5-a to read as follows:
5-a. Notice of an adverse determination made by a utilization review agent in relation to a step therapy protocol override determination request shall be made in writing to the enrollee or the enrollee's authorized representative and the enrollee's prescribing health care professional as defined in subdivision six of section forty-nine hundred of this title, and shall include:
(a) the reasons for the determination including the clinical rationale, if any;
(b) instructions on how to initiate standard and expedited appeals pursuant to section forty-nine hundred four of this title and an external appeal pursuant to section forty-nine hundred fourteen of this article;
(c) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal.
§ 5. This act shall take effect on the ninetieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.